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ly correlated with estimated pulmonary artery pressure, 
right ventricular Tei index, and tricuspid E/A ratio. Addition-
ally, we found that CDH infants with NT-proBNP  1 11,500 pg/
ml experienced a worse prognosis.  Conclusions: We dem-
onstrated that PH is associated with NT-proBNP elevation 
and diastolic impairment in CDH infants. Early elevations in 
NT-proBNP levels seem to alert for a subset of CDH infants 
with worse prognosis.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Despite many advances in the management of con-
genital diaphragmatic hernia (CDH), the outcome of af-
fected infants remains unpredictable and varies from 
year to year even in experienced teams with predeter-
mined treatment protocols. Its morbidity and mortality 
is largely dependent of pulmonary hypertension (PH) 
and hypoplasia  [1] . Pulmonary hypoplasia installs during 
prenatal development  [2–4] and limited possibilities exist 
to attenuate it  [5, 6] . PH is likely secondary to pulmonary 
 Key Words 
 N-terminal-pro-B type natriuretic peptide   Congenital 
diaphragmatic hernia   Pulmonary hypertension   
Cardiac function   Diastole 
 Abstract 
 Objective: In congenital diaphragmatic hernia (CDH) the se-
verity of pulmonary hypertension (PH) is considered, by sev-
eral authors, determinant of clinical outcome. Plasmatic N-
terminal-pro-B type natriuretic peptide (NT-proBNP) might 
be useful in diagnosis and management of PH in newborns, 
although its interest in CDH infants remains to be defined. 
Early NT-proBNP levels were assessed in CDH infants and 
correlated with cardiovascular echocardiographic parame-
ters.  Patients and Methods: 28 newborns, CDH and age-
matched controls were enrolled in a prospective study. Clin-
ical condition, NT-proBNP plasmatic levels, echo parameters 
of PH and biventricular function were assessed at 24 h after 
delivery as well as survival outcome.  Results: Estimated 
mean pulmonary pressure and NT-proBNP were significant-
ly higher in CDH than control infants. NT-proBNP significant-
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hypoplasia and associated underdeveloped vascular bed, 
which for some authors is a major determinant of post-
natal clinical outcome  [7] . For this reason, evaluation of 
PH severity is considered important for management of 
CDH infants in several centers  [1] and its assessment is 
crucial to decide upon pulmonary vasodilator therapy as 
well as to monitor its effects  [8, 9] . Furthermore, for these 
authors the decision for surgical repair should be based 
on evidence of PH stabilization  [10] . Assessment of PH is 
mainly based on clinical and echocardiographic estima-
tion. However, echocardiographic evaluation is not al-
ways available and it is somewhat observer-dependent 
and technically demanding in CDH infants due to the 
presence of abdominal organs in thoracic cavity. An easy 
and reliable method to assess PH remains to be defined. 
On the other hand, PH could induce cardiac dysfunction 
due to right ventricular (RV) overload, although this as-
pect has not been clearly elucidated in CDH infants  [11] .
 B-type natriuretic peptide (BNP) is a hormone of pre-
dominantly ventricular origin produced and released in 
response to increased ventricular wall stress  [12, 13] . N-
terminal-pro-BNP (NT-proBNP), the amino-terminal 
portion of the preprohormone, is secreted into the pe-
ripheral blood in equimolar portions to BNP, but it has 
a longer half-life and is easier to measure  [13] . In recent 
years, NT-proBNP has emerged as a very sensitive bio-
chemical marker for ventricular dysfunction in adult 
heart failure, the plasmatic level of which could be used 
as a guide for the response to therapy and to predict 
prognosis  [14] . However, in children the knowledge 
about the significance of plasma levels of NT-proBNP is 
still limited. In healthy children, studies have shown 
that NT-proBNP levels are elevated soon after birth 
reaching its peak at 24 h of life decreasing thereafter up 
to 4 months and remaining unchanged until the age
of 15  [15–19] . NT-proBNP levels are elevated in chil-
dren with congenital heart disease or cardiomyopathy 
 [20–22] . In infants, it was also demonstrated that NT-
proBNP is elevated in symptomatic patent ductus arte-
riosus in preterms  [23, 24] and PH  [25] . Additionally, in 
newborns submitted to cardiac catheterization due to 
critical pulmonary stenosis or atresia, NT-proBNP cor-
relates with hemodynamic measured RV pressure  [26] . 
However, assessment of plasmatic NT-proBNP and its 
clinical usefulness in newborns with PH due to CDH 
remains to be defined.
 The aim of this study was to compare echocardio-
graphic parameters of cardiac function and plasmatic 
NT-proBNP levels, at 24 h after birth, between CDH and 
healthy infants.
 Materials and Methods 
 Study Subjects 
 From January 2004 to October 2006, we enrolled in this study 
term or near-term newborns ( 6 36 weeks’ gestation) admitted to 
our hospital’s neonatal intensive care unit (NICU) or normal 
newborn nursery. Two groups were defined: (1) a control group 
that included healthy infants, and (2) a CDH group that  included 
consecutive newborns with left-sided CDH (Bochdalek hernia) 
without heart defect. Sample size was calculated in order to detect 
a difference of at least 2 units between groups’ means, assuming 
a standard deviation of 1 unit, with a 95% confidence level (5%   
level) and at least 85% power, in an independent samples Student’s 
t test. Thus, we estimated having to recruit at least 20 newborns 
(10 CDH patients and 10 controls).
 Healthy infants were identified from patients that needed 
blood sampling, at the second day of life, for clinical reasons not 
related to this study, specifically by suspected sepsis or physiolog-
ic jaundice. In these infants, echocardiography was performed 
immediately before blood was drawn for functional evaluation 
and exclusion of congenital heart disease. Physiologic jaundice is 
defined as a benign condition with bilirubin levels  ! 15 mg/day. 
Infants with confirmed sepsis or newborns with transient tachy-
pnea as well as congenital heart disease, PH or hemodynamic sig-
nificant ductus arteriosus were excluded from this study.
 In CDH newborns, echocardiography was done immediately 
before blood was drawn that is performed routinely at 24 h of life. 
Clinical management of CDH infants in our NICU include de-
layed surgical repair after extensive preoperative stabilization 
with ‘gentle ventilation’ and inhaled nitric oxide treatment, if
necessary. We could not manage patients with extracorporeal 
membrane oxygenation (ECMO) since it is not available in our 
center.
 NT-proBNP was measured in the blood drawn in these two 
groups.
 Demographic data from both study groups included postmen-
strual age at delivery, gender, birth weight as well as 1- and 5-min 
Apgar scores. At the moment of blood sampling, data gathered 
included systolic, mean and diastolic blood pressure, requirement 
of inotropic support, pulmonary vasodilator therapy as well as of 
mechanical ventilation, current ventilator settings and blood gas-
es. In CDH infants the oxygenation index and the ventilatory in-
dex were calculated. Simultaneously, echocardiographic param-
eters and plasmatic NT-proBNP levels were recorded. Addition-
ally, we recorded the day of surgery as well as survival taking into 
account that survivor newborn was defined as alive at discharge 
from NICU.
 The study was approved by the Institutional Review Board of 
our hospital and informed consent was obtained from the parents 
of all participants. No infant, neither case nor control, received 
additional blood collection, other than routine blood sampling, 
as a consequence of this study, as NT-proBNP usually could be 
measured in the routine amount of blood sample. Data collected 
from this study were not used to influence medical decision-mak-
ing. Management of each infant was left to the criteria of the at-
tending physician, according to the treatment protocol of our 
NICU. NT-proBNP plasmatic measurement was not achieved in 
5 CDH newborns, due to insufficient sample.
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 Echocardiographic Assessment 
 The echocardiographic assessment was designed as part of the 
infants’ routine care or additionally to that, at no cost to the pa-
tient. All examinations were performed with an echograph Aloka 
(Tokyo, Japan) using a 5-MHz probe, by the same investigator 
(M.J.B.). Once echocardiography always preceded blood sam-
pling, the investigator interpreting echocardiography was blind-
ed to NT-proBNP levels, although not blinded for control versus 
CDH groups.
 In infants from control and CDH groups, echocardiography 
was performed to exclude congenital heart disease and to ascer-
tain the following parameters: (i) RV and left ventricular (LV) 
systolic and end-diastolic dimensions (M-mode, parasternal ven-
tricular short-axis view); (ii) mitral and tricuspid diastolic dimen-
sions (2D, 4-chamber view); (iii) dimensions of the right and left 
pulmonary arteries (RPA and LPA); (iv) orientation of ventricular 
septum (existence of bulging to left ventricle); (v) ductus arterio-
sus and foramen oval patency and shunt direction; (vi) existence 
and quantification of tricuspid regurgitation as well as RV-right 
atrium (RA) gradient; (vii) RV outflow acceleration time (OAT); 
(viii) RV outflow ejection time; (ix) peak flow velocity of A and E 
wave at mitral and tricuspid valves; (x) time from cessation of tri-
cuspid and mitral inflow to onset of tricuspid and mitral inflow, 
respectively, in the next cardiac cycle. These allowed the estima-
tion of: (xi) mitral-to-tricuspid ratio; (xii) LPA-to-RPA ratio; (xiii) 
estimated right ventricular systolic pressure (RVSP) through the 
formula: RVSP = tricuspid regurgitation gradient + RA pressure, 
assuming a normal RA pressure of 4 mm Hg  [27, 28] ; (xiv) esti-
mated mean pulmonary artery pressure (MPAP), through the for-
mula MPAP = 90 – (0.62  ! OAT)  [29] ; (xv) tricuspid and mitral 
E/A ratios; (xvi) the RV and LV Tei index, as described by Tei et 
al.  [30] , assessed as Tei index = (time from cessation of tricuspid 
or mitral inflow to onset of tricuspid or mitral inflow in the next 
cardiac cycle – RV or LV outflow ejection time)/RV or LV outflow 
ejection time; (xvii) RV OAT to RV outflow ejection time, a quan-
titative predictor of peak PA pressure in infants  [31] . Measure-
ments were obtained in 3 consecutive cardiac cycles and averaged 
to account for respiratory variation.
 Taking into account the distinct characteristics of RV and LV, 
we evaluate ventricular function using different parameters: (i) 
global function, using the Tei index in RV and LV  [32] ; (ii) sys-
tolic function, with peak pulmonary flow velocity in RV  [33] and 
ejection fraction in LV; (iii) diastolic function, tricuspid and mi-
tral E/A ratio in RV and LV, respectively.
 In CDH newborns the echocardiographic window is limited 
due to the intrathoracic position of abdominal organs and me-
chanical ventilation. Nevertheless, the echocardiographic proto-
col was completed in all CDH patients. For that purpose the sub-
costal window or right-sided parasternal window was sometimes 
used instead of the classical echo windows.
 NT-proBNP Measurement 
 The plasmatic level of NT-proBNP was evaluated at 24 h of life 
in every control infant and in 13 of the 18 CDH patients. NT-
proBNP levels were measured with a chemiluminescent immuno-
assay kit (Roche Diagnostics, Portugal) on an Elecsys 2010 ana-
lyzer. Venous blood samples were collected in EDTA-containing 
tubes.
 Statistical Analysis 
 Descriptive statistics were presented as mean and standard de-
viation as appropriate. Plasma NT-proBNP measurements resem-
bled a log-normal distribution, so natural logarithmic transfor-
mation was used to normalize the distribution when indicated. 
Comparisons between groups were performed using Fisher’s ex-
act test for categorical variables. For continuous variables com-
parisons, we used Student’s t test if normality of the distributions 
could be assumed or non-parametric Mann-Whitney U test if 
normality could not be assumed. In order to test the normality of 
the distribution of the continuous variables the one-sample Kol-
mogorov-Smirnov goodness-of-fit test was applied. Pearson cor-
relation coefficients were calculated to evaluate the relationship 
between NT-proBNP and estimated pulmonary pressure as well 
as the echocardiographic parameters of cardiac function. To de-
scribe the discriminative power of plasma NT-proBNP measure-
ment concerning mortality outcome, sensitivity and specificity 
were calculated for various levels of this variable, a receiver oper-
ating characteristic (ROC) curve was drawn. Given the small 
sample size it was not possible to analyze the prognostic value of 
plasma NT-proBNP measurements using appropriate multivari-
ate modeling methods. For hypothesis testing, a value of p  ! 0.05 
was considered significant.
 Results 
 In this study, we evaluated 28 infants, 10 in the control 
group and 18 in the CDH group. In the CDH group, NT-
proBNP was evaluated only in 13 newborns, due to an 
insufficient amount of blood for the measurement. The 
demographic data of CDH infants are presented in  ta-
ble 1 . Excluding Apgar scores in CDH infants, no signif-
icant differences were identified with regards to birth 
weight, gestational age and gender.
 The clinical conditions of CDH newborns, regarding 
the requirement of inotropic support, pulmonary vaso-
dilator therapy as well as day of surgery and outcome, 
are summarized in  table 2 . NT-proBNP levels were sig-
nificantly higher in CDH than in the control group 
( fig. 1 ).
 Evaluated echocardiographic parameters in control 
and CDH groups are presented in  table 3 . In newborns 
with CDH, estimated MPAPs were significantly higher 
when compared to the control group reflecting an in-
creased afterload to the RV. All newborns from CDH 
groups had some echocardiographic evidence of PH, 
bulging of interventricular septum and right-to-left shunt 
at the level of ductus arteriosus and foramen ovale. Mor-
phologically, RV systolic and diastolic dimensions were 
significantly higher in the CDH group than the control 
group, whereas LV systolic and diastolic dimensions were 
significantly lower in the CDH than the control group. 
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Additionally, mitral-to-tricuspid and LV-to-RV diastolic 
M-mode ratios were significantly lower in the CDH than 
the control group.
 Evaluation of global function parameters revealed 
that the RV Tei index was significantly higher in the CDH 
than the control group. Regarding systolic function, in 
comparison to the control group, CDH infants had a 
slightly depressed RV function as evidenced by a signifi-
cant decrease in peak pulmonary velocity, whilst the LV 
systolic function was enhanced as demonstrated by a 
higher LV ejection fraction. Both RV and LV diastolic pa-
rameters (E/A auriculo-ventricular ratios) were signifi-
Table 2. Clinical data of CDH newborns
Infant Inotropic support Vasodilator
therapy
Mechanical ventilation Day of
surgery
Day of
discharge
1 Yes (dopamine and dobutamine) Yes (iNO) SIMV (for 24 days) D14 D24 (death)
2 No No SIMV (for 10 days) D7 D14 (alive)
3 Yes (dopamine and dobutamine) No SIMV (for 2 days) No D2 (death)
4 Yes (dopamine and dobutamine) No SIMV (for 2 days) No D2 (death)
5 No No SIMV (for 6 days) D4 D13 (alive)
6 Yes (dopamine and dobutamine) No SIMV (for 12 days) D4 D18 (alive)
7 No No SIMV (for 6 days) D4 D11 (alive)
8 Yes (dopamine) No SIMV (for 7 days) D4 D24 (alive)
9 Yes (dopamine and dobutamine) No SIMV (for 3 days) D3 D3 (death)
10 No No SIMV (for 14 days) D5 D21 (alive)
11 Yes (dopamine and dobutamine) Yes (iNO) HFVO (for 89 days) D42 D89 (death)
12 Yes (dopamine and dobutamine) Yes (iNO) HFVO (for 20 days) D9 D38 (alive)
13 Yes (dopamine) No SIMV (for 7 days) D3 D17 (alive)
14 Yes (dopamine) Yes (iNO) SIMV (for 6 days) No D6 (death)
15 Yes (dobutamine) Yes (iNO) SIMV (for 35 days) D14 D46 (alive)
16 Yes (dopamine) Yes (iNO) SIMV (for 8 days) D8 D21 (death)
17 Yes (dopamine) Yes (iNO) SIMV (for 11 days) No D11 (death)
18 Yes (dopamine) Yes (iNO) SIMV (for 13 days) D4 D13 (death)
iNO = Inhaled nitric oxide; SIMV = synchronous intermittent mandatory ventilation; HFOV = high-frequency oscillatory ventila-
tion.
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 Fig. 1. Plasmatic NT-proBNP level is significantly increased in new-
borns with CDH compared to control ( * p  ! 0.05 vs. control). 
Table 1. Demographic data
Groups studied p value
control group
(n = 10)
CDH group
(n = 18)
Birth weight, g 3,2368612 2,9548451 0.1751
Gestational age, weeks 38.381.3 37.781.7 0.4301
Male gender 9 (90) 12 (67) 0.3642
1-min Apgar, median 9 7 0.0033
5-min Apgar, median 10 8 <0.0013
Hours of measurement 2681.2 2380.9 0.4631
CDH = Congenital diaphragmatic hernia. For continuous 
variables, values are expressed as numbers of infants (%) or means 
8 SD.
1 t test for independent samples. 2 Fisher’s exact test. 3 Mann-
Whitney non-parametric test.
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cantly lower in the CDH group than the control group, 
suggesting significant RV and LV diastolic impairment 
in the CDH group. We found significant correlations be-
tween NT-proBNP and estimated pulmonary mean pres-
sure (r = 0.45; p = 0.03), RV Tei index (r = –0.50; p = 0.02) 
and tricuspid E/A ratio (r = –0.46; p = 0.03).
 Comparison between Survivors and Non-Survivors 
 Nine infants of the CDH group died. A comparison 
between survivors and non-survivors is presented in  ta-
ble 4 . NT-proBNP plasmatic level, at the end of the first 
day of life, was significantly higher in non-survivor than 
in survivor newborns. There are no differences between 
both groups concerning birth weight, gestational age, 1- 
and 5-min Apgar or mean arterial blood pressure. Re-
garding pulmonary indices, we detected significant dif-
ferences between survivor and non-survivor infants. On 
echo parameters, we identified that estimated mean pul-
monary pressures were significantly higher in non-sur-
vivor than in survivor CDH infants, whereas pulmonary 
acceleration to ejection time and tricuspid E/A ratios 
were significant lower in non-survivor than in survivor 
CDH infants.
 The NT-proBNP level of 11,500 pg/ml was the value 
with highest specificity and sensitivity to separate survi-
vor and non-survivor CDH infants in ROC curves, in 
CDH infants. According to the ROC curve, the cutoff 
NT-proBNP level of 11,500 pg/ml has 100% sensitivity 
and 67% specificity. Infants with a plasmatic NT-proBNP 
at 24 h of life  1 11,500 pg/ml had a significantly lower sur-
vival rate than those with plasmatic NT-proBNP at 24 h 
of life  ! 11,500 pg/ml.
Table 3. Data of echocardiography in control and CDH infants at 24 h after birth
Control group CDH group pa
Pulmonary pressure
Pulmonary systolic pressure, mm Hgb – 56.0818.6
Pulmonary mean pressure, mm Hgb 41.6814.9 64.0814.9 0.001
Heart dimensions
Right ventricle
Tricuspid diameter, mm 9.4581.00 10.4582.00 0.055
RV systole M-mode, mm 5.7582.70 9.4084.70 0.017
RV diastole M-mode, mm 7.0082.15 11.3083.60 0.009
Left ventricle
Mitral diameter, mm 9.9081.80 8.1581.80 0.019
LV systole M-mode, mm 10.4081.10 7.9083.90 0.023
LV diastole M-mode, mm 16.0081.40 14.3083.50 0.025
Ratios
Mitral-to-tricuspid 1.0380.15 0.7980.15 <0.001
RPA-to-LPA 1.1580.30 1.1080.20 0.071
LV-to-RV diastole M-mode 2.3580.65 1.1080.40 0.002
Heart function
Global function
RV Tei index 0.2180.05 0.2880.09 0.002
LV Tei index 0.2280.17 0.2380.10 0.674
Systolic function
Peak pulmonary velocity, m/s 0.8080.18 0.5980.12 0.003
LV ejection fraction, % 6789 80817 0.02
Diastolic function
Tricuspid E/A ratio 0.9680.11 0.8080.13 <0.001
Mitral E/A ratio 1.0080.44 0.8180.13 0.019
Results are presented as median 8 interquartile range.
CDH = Congenital diaphragmatic hernia; RPA = right pulmonary artery; LPA = left pulmonary artery;
LV = left ventricle; RV = right ventricle.
a Mann-Whitney non-parametric test. b Both mean and systolic pulmonary pressure were estimated.
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 Discussion 
 In our study, we demonstrated that PH is associated 
with diastolic impairment and higher NT-proBNP levels 
measured at 24 h of life elevation in CDH infants. Early 
elevations in NT-proBNP levels seem to alert for a subset 
of CDH infants with worse prognosis.
 In recent years, PH has emerged for many authors as 
a key determinant of outcome in CDH infants  [1] . Con-
sequently, PH progressively becomes one of the therapeu-
tic targets in managing these newborns. In fact, in sev-
eral therapeutic approaches (delayed surgery, high-fre-
quency ventilation, nitric oxide inhalation, ECMO and 
other pulmonary vasodilators), one of the aims is con-
trolling PH, whereas the decision for surgical repair is 
based on evidence of PH stabilization  [9] . Since accurate 
evaluation of pulmonary artery pressure with a Swan-
Ganz catheter, in newborns, is not achievable, echocar-
diography is used to assess PH. Nevertheless, echocar-
diography is not available 24 h a day in all centers dealing 
with CDH infants and reliable parameters are not easy to 
quantify, most of them being observer-dependent. In this 
setting, non-invasive and examiner-independent param-
eters could be particularly useful to manage CDH infants 
with PH, but should be available in a short time frame 
 [34] .
 In this context, we investigated the potential signifi-
cance of plasmatic NT-proBNP levels in CDH infants. 
The elevated levels of NT-proBNP that we found in CDH 
infants should be secondary to PH. Previous studies have 
demonstrated both in adults  [35] and infants  [24] that 
plasmatic NT-proBNP levels are elevated in patients with 
Table 4. Parameters studied at 24 h of life in newborns with CDH according to survival
Survivors (n = 9) Non-survivors (n = 9) p
NT-proBNP, mg/ml 6,23084,743 22,65385,653 0.0092
log[NT-proBNP] * 8.7380.87 10.1480.30 0.0031
Demographic data
Birth weight, g * 3,0988415 2,8828620 0.2382
Gestational age, weeks * 3881.4 3782.5 0.6861
Male gender, n (%) 6 (67) 6 (67) 0.9993
1-min Apgar 881 783 0.212
5-min Apgar 981 883 0.1782
Mean arterial blood pressure, mm Hg * 4088 41810 0.4491
Pulmonary indices
PaO2 80820 42816 0.0032
PaCO2 46815 58816 0.0632
FiO2 0.380.6 1.080.0 0.0022
MAP 6.981.9 12.881.5 0.0032
Oxygenation index 2.285.0 28.8824.26 0.0032
Ventilatory index 2438141 8798139 0.0032
Echo indices
Mitral-to-tricuspid ratio 0.8280.20 0.7780.07 0.5962
LV-to-RV diastole M-mode ratio 1.281.0 1.180.2 0.4002
Pulmonary systolic pressure, mm Hg 42819 58819 0.0772
Pulmonary mean pressure, mm Hg 53811 6880.6 0.0092
RV Tei index 0.2780.05 0.3180.11 0.4112
LV Tei index 0.2280.09 0.2380.07 0.9992
Peak pulmonary velocity, m/s 0.5880.17 0.628011 0.7002
Pulmonary acceleration/ejection time 0.3380.1 0.2280.03 0.0022
Tricuspid E/A ratio 0.8580.11 0.7680.29 0.0202
Mitral E/A ratio 0.8280.15 0.7980.23 0.1912
Results are presented as median 8 interquartile range unless otherwise indicated. * mean 8 standard de-
viation.
1 t test. 2 Mann-Whitney non-parametric test. 3 Fisher’s exact test.
PaO2 = Oxygen arterial partial pressure; PaCO2 = carbon dioxide arterial partial pressure; MAP = mean 
airways pressure; LV = left ventricle; RV = right ventricle.
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PH. Although already demonstrated in adults, the cor-
relation between pulmonary artery pressure and NT-
proBNP has not previously been established in infants. In 
the present study we demonstrated that both in controls 
and CDH infants the plasmatic NT-proBNP level corre-
lates with estimated mean pulmonary pressure. In CDH 
infants, invasive measurement of pulmonary pressure 
and hemodynamic parameters of cardiac function is not 
feasible. Currently, magnetic resonance imaging is em-
ployed in children and adults to evaluate RV, but this is 
also not reasonable in critical CDH infants.
 We decided to measure the NT-proBNP at 24 h of life 
basically for two reasons: (1) it has been previously dem-
onstrated that NT-proBNP reaches its peak by the end 
of the first day of life in healthy infants  [15] , and (2) it is 
well known that a number of CDH infants do well dur-
ing the first day of life (‘honeymoon period’), but after 
this period the clinical status of the most severely af-
fected subset of CDH infants deteriorates. For these rea-
sons, the evaluation of NT-proBNP at the end of the first 
24 h of life appears appealing, since it could alert for 
those babies that will require more sophisticated meth-
ods to support their life such as ECMO. In fact, we hy-
pothesize that the measurement of NT-proBNP could 
separate two groups of CDH infants with different prog-
noses. In our study, plasmatic NT-proBNP  1 11,500 pg/
ml selected those CDH infants that experienced a worse 
prognosis.
 In our study, we performed an exhaustive cardiac 
function assessment by echocardiography which revealed 
significant adaptation in biventricular function, both in 
systole and diastole. The systolic RV function is impaired 
in CDH infants, probably in relation with higher RV af-
terload. In CDH infants we found an increase in LV ejec-
tion fraction, which could be related with relative under-
filling of the LV as well as with end-systolic septal bulging 
 [36] . In fact, it was previously demonstrated that the end-
systolic leftward ventricular septal shift in situations with 
RV pressure overload results in isolated augmentation of 
systolic shortening in the septal-to-free wall dimensions 
 [36] . Whereas the potential mechanisms for LV filling ab-
normalities have been pointed out above, impairment of 
RV diastolic function might be directly related with in-
creased RV afterload. In fact, afterload is a major deter-
minant of diastolic function. Severe afterload elevations 
slow down the relaxation rate and elevate diastolic filling 
pressures due to an upward shift of the end-diastolic 
pressure-volume relation  [37, 38] . Additionally, hypoxia 
and acidosis, reflected as lower Apgar indices observed in 
CDH newborns, also impair myocardial relaxation and 
might therefore further contribute to the impairment of 
both RV and LV diastolic function. The echocardio-
graphic pattern of impaired relaxation (E/A  ! 1) observed 
in both ventricles of CDH patients in the present study 
further reinforce our hypothesis. Global RV function 
evaluated by the Tei index is depressed in CDH infants. 
This finding is in line with the recent studies of Grignola 
et al.  [39] who demonstrated that the RV Tei index is a 
sensitive marker of RV dysfunction in the settings of 
acute PH.
 In the present study we documented a significant cor-
relation between NT-proBNP and estimated mean pul-
monary pressure as well as some echocardiographic indi-
ces of ventricular function (as RV Tei index and tricuspid 
E/A ratio). The increase of plasmatic NT-proBNP proba-
bly reflects ventricular adaptation to pressure overload 
secondary to PH and could be defined as a non-specific 
parameter of RV overload. Plasmatic NT-proBNP prob-
ably fluctuates according to the clinical condition of CDH 
newborns, and therapeutic management that modifies 
ventricular overload could change the level of this bio-
chemical marker. Nevertheless, it will always reflect the 
actual hemodynamic status of the infants and their re-
sponse to the treatment.
 As previously referred to by several authors, in our 
study we documented that non-survivor CDH newborns 
required more aggressive ventilation with impaired blood 
gas exchange. In fact, some parameters derived from
oxygenation status had been suggested as a potential 
marker of prognosis  [40] . The comparison of survivor 
and non-survivor CDH infants demonstrated that NT-
proBNP and estimated pulmonary mean pressure were 
significantly different in both groups, probably reflecting 
the increasing severity of the disease. Nevertheless, with 
the exception of pulmonary acceleration to ejection time 
and E/A tricuspid ratios, no other parameters of heart 
function were significantly different in both groups. We 
believe that this is due to a failure of echocardiography to 
accurately evaluate heart function and effectively differ-
entiate degrees of severity in impairment of heart dys-
function, instead of lack of increased adjustments in car-
diac function related to PH.
 In conclusion, we demonstrated that PH in CDH in-
fants induces cardiac function adaptations, which could 
be evaluated not only by echocardiography but also by 
plasmatic NT-proBNP. Although this study was carried 
out in a small number of patients, this biochemical mark-
er could be an accurate indicator of the severity of the 
clinical condition and PH in CDH newborns. Thus, it 
seems reasonable to suggest that CDH infants with early 
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elevations in NT-proBNP should alert for a subset of 
CDH infants with worse prognosis that should be consid-
ered for further study, pulmonary vasodilator therapy or 
transfer to an ECMO center.
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